Ion Exchange (india) Ltd. · NSE:IONEXCHANG
Ion Exchange (india) — Q1 FY2026-27 Earnings Presentation
39 slides from Ion Exchange (india)'s earnings presentation, Aug 10, 2026
Slide 1: Submission of Earnings Presentation to Stock Exchanges
August 10, 2026 To BSE Limited National Stock Exchange of India Limited The Corporate Relationship Dept. Exchange Plaza, C-1, Block- G, P.J. Towers, Dalal Street Bandra Kurla Complex, Bandra (East), Mumbai-400 001 Mumbai-400 051 Scrip Code: 500214 Symbol: IONEXCHANG Sub.: Submission of Earnings Pres
Slide 2: Earnings Presentation Q1-FY27
Earnings Presentation Q1-FY27
Slide 3: Company Snapshot
Company Snapshot OPERATIONS IN 62 + 360° TOTAL WATER & YEARS OF 50 + ENVIRONMENT MANAGEMENT EXPERTISE COUNTRIES SERVING WORLD CLASS ONE OF ASIA’S LARGEST EXPORTS ACROSS INDUSTRIES, MANUFACTURING FACILITIES SERVICE NETWORKS CONTINENTS INSTITUTIONS, HOMES & COMMUNITIES GLOBAL ASSEMBLY HUBS IN ADVANCED
Slide 4: Total Water & Environment Management Solutions
Total Water & Environment Management Solutions Management of Specialty Resins / Adsorbents / Membranes / Industrial Wastewater Treatment Process Water Chemicals / Enzymes for Purification & Recycle & Zero Liquid Discharge Concentration Drinking Water Treatment Process Water Treatment – Ion Exchange
Slide 5: Capabilities
Capabilities Leaders in Resins, Membranes & Chemicals, with a Unique End-to-End Portfolio Spanning Solutions, Digital & Services RESINS MEMBRANES CHEMICALS SOLUTIONS SERVICES DIGITAL 1 2 3 4 5 6 7 8 SOURCE WATER & PROCESS WATER HIGH PURITY WATER ULTRA PURE INDUSTRIAL WASTEWATER ZERO LIQUID DISCHARGE
Slide 6: Global Presence
Global Presence 50+ COUNTRIES SERVED 30% INTERNATIONAL REVENUE SHARE 14 GLOBAL MANUFACTURING FACILITIES & ASSEMBLY CENTRES 200,000+ GLOBAL INSTALLATIONS Our Global Offices
Slide 7: Global Manufacturing Facilities
Global Manufacturing Facilities Ankleshwar, Gujarat Roha, Maharashtra Verna, Goa Resins Manufacturing - Exports Non-Solvent Resins Centre of Membrane Excellence Patancheru, Telangana Saudi Arabia Portugal Chemicals Manufacturing Chemical Blending Facility MAPRIL, Manufacturing Facility
Slide 8: Global Manufacturing Facilities
Global Manufacturing Facilities Hosur, Tamil Nadu Verna, Goa Wada, Maharashtra Palaspe, Maharashtra Standard Systems Assembly Standard Membrane Systems Standard Systems Assembly Large System Assembly UAE South Africa Indonesia Bangladesh Assembly Unit, ICV Certified Facility Manufacturing Facility A
Slide 9: Current vs New Reporting Segments
Current vs New Reporting Segments Ion Exchange (India) Ltd. Current Reporting Engineering Chemicals Consumer Products New Reporting Institutional Treatment Industrial Lifecycle Specialty Consumer Solutions Products Services Chemicals Products
Slide 10: New Reporting Segments
New Reporting Segments TREATMENT INDUSTRIAL LIFECYCLE SPECIALTY CONSUMER SOLUTIONS PRODUCTS SERVICES CHEMICALS PRODUCTS 1 2 3 4 5 ▪ Water Treatment ▪ Standard Water ▪ Operations & ▪ Water Treatment ▪ Home Water Solutions ▪ Ultra Pure Water Treatment Solutions Maintenance (O&M) Chemicals ▪ Community
Slide 11: Financial Overview Q1-FY27
€ Financial Overview Q1-FY27
Slide 12: Q1-FY27 Financial Highlights
Q1-FY27 Financial Highlights Q1-FY27 Performance (Standalone) Q1-FY27 Performance (Consolidated) INR 6,356 Mn INR 307 Mn 4.83 % INR 7,005 Mn INR 318 Mn 4.54 % Operating EBITDA Operating EBITDA Operating EBITDA Operating Income Operating EBITDA Operating Income Margins Margins INR 114 Mn 1.79 % INR 0
Slide 13: Quarterly Consolidated Segmental Breakup: Treatment Solutions
Quarterly Consolidated Segmental Breakup Treatment Solutions INR Mn 2,099 1,839 Q1-FY27 Performance Highlights ▪ Revenue growth of 14% ▪ GCC Dispatches resumed .. To pick up momentum ▪ Margins continue to be impacted by legacy projects Future Growth Drivers 168 ▪ Existing backlog liquidation ▪ New e
Slide 14: Quarterly Consolidated Segmental Breakup: Industrial Products
Quarterly Consolidated Segmental Breakup Industrial Products INR Mn 1,051 922 Q1-FY27 Performance Highlights ▪ Revenue growth of 14% ▪ EBIT% up from 5.53% to 11.89% ▪ Strong performance by Standard Water Treatment Solutions and Membranes 125 Future Growth Drivers 51 ▪ Manufacturing expansion for UF
Slide 15: Quarterly Consolidated Segmental Breakup: Lifecycle Services
Quarterly Consolidated Segmental Breakup Lifecycle Services INR Mn 716 Q1-FY27 Performance Highlights 559 ▪ Revenue growth of 28% ▪ EBIT% down from 10.55% to 9.92% due to input costs ▪ Focus on O&M and Consumables Future Growth Drivers 71 ▪ Expanding solution offerings 59 ▪ Retrofit business and BOO
Slide 16: Quarterly Consolidated Segmental Breakup: Specialty Chemicals
Quarterly Consolidated Segmental Breakup Specialty Chemicals INR Mn 2,297 1,889 Q1-FY27 Performance Highlights ▪ Revenue growth of 21% ▪ EBIT down to 9.71% due to geopolitical impact ▪ Higher costs due to Roha facility capex 463 223 Future Growth Drivers ▪ Increased offtake from Roha Plant ▪ Pharma
Slide 17: Quarterly Consolidated Segmental Breakup: Consumer Products
Quarterly Consolidated Segmental Breakup Consumer Products INR Mn 1,124 Q1-FY27 Performance Highlights 843 ▪ Revenue Growth of 33% ▪ EBIT slightly up from -0.59% to -0.27% ▪ Strong growth across all key product lines Future Growth Drivers ▪ Growth in the Softener market ▪ Wellness product offerings
Slide 18: Quarterly Consolidated Financial Performance
Quarterly Consolidated Financial Performance INCOME STATEMENT (INR Mn) Q1-FY27 Q1-FY26 Y-o-Y Q4-FY26 Q-o-Q Operating Income 7,005 5,832 20.1% 8,633 (18.9)% Expenses 6,687 5,205 28.5% 8,434 (20.7)% Operating EBITDA 318 627 (49.3)% 199 59.8% Operating EBITDA Margins (%) 4.54% 10.75% (622) bps 2.31% 22
Slide 19: Quarterly Standalone Financial Performance
Quarterly Standalone Financial Performance INCOME STATEMENT (INR Mn) Q1-FY27 Q1-FY26 Y-o-Y Q4-FY26 Q-o-Q Operating Income 6,356 5,178 22.8% 8,139 (21.9)% Expenses 6,049 4,616 31.0% 8,028 (24.7)% Operating EBITDA 307 562 (45.4)% 111 176.6% Operating EBITDA Margins (%) 4.83% 10.85% (602) bps 1.36% 347
Slide 20: Historic Financial Overview
Historic Financial Overview
Slide 21: Historical Standalone Financial Performance
Historical Standalone Financial Performance INCOME STATEMENT (INR Mn) FY23 FY24 FY25 FY26 Q1-FY27 Operating Income 18,923 21,800 25,401 26,789 6,356 Expenses 16,544 19,129 22,549 24,946 6,049 Operating EBITDA 2,379 2,671 2,852 1,843 307 Operating EBITDA Margins (%) 12.57% 12.25% 11.23% 6.88% 4.83% D
Slide 22: Historical Standalone Balance Sheet
Historical Standalone Balance Sheet PARTICULARS (INR Mn) FY24 FY25 FY26 PARTICULARS (INR Mn) FY24 FY25 FY26 EQUITIES & LIABILITIES ASSETS Equity Non-Current Assets (A) Property, Plant and Equipment 2,149 2,414 5,851 (A) Equity Share Capital 147 147 147 (B) Capital Work-in-progress 607 3,170 1,747 (B
Slide 23: Historical Consolidated Financial Performance
Historical Consolidated Financial Performance INCOME STATEMENT (INR Mn) FY23 FY24 FY25 FY26 Q1-FY27 Operating Income 19,896 23,479 27,371 29,148 7,005 Expenses 17,346 20,759 24,432 27,046 6,687 Operating EBITDA 2,550 2,720 2,939 2,102 318 Operating EBITDA Margins (%) 12.82% 11.58% 10.74% 7.21% 4.54%
Slide 24: Historical Consolidated Balance Sheet
Historical Consolidated Balance Sheet PARTICULARS (INR Mn) FY24 FY25 FY26 PARTICULARS (INR Mn) FY24 FY25 FY26 EQUITIES & LIABILITIES ASSETS Equity Non-Current Assets (A) Equity Share Capital 142 142 142 (A) Property, Plant and Equipment 3,018 3,280 6,853 (B) Other Equity 10,037 11,937 13,248 (B) Cap
Slide 25: Consolidated Historical Financial Performance: Revenues
Consolidated Historical Financial Performance Revenues (INR Mn) 29,148 Summary 27,371 ▪ Growth till FY25 driven by strong backlog ▪ FY26 growth impacted by geopolitical challenges 23,479 ▪ Chemicals and CPD Segments growing strongly 19,896 Future Actions ▪ Treatment Solutions growth from overseas ba
Slide 26: Consolidated Historical Financial Performance: Operating EBITDA
Consolidated Historical Financial Performance Operating EBITDA (INR Mn) Summary 2,939 ▪ Impact of Higher Cost profile in certain EPC contracts 2,720 2,550 ▪ Slowed execution of UP Contract 2,102 ▪ Roha Facility Costs consequent to plant commissioning in FY 26 12.82% 11.58% ▪ Impact of West Asia cris
Slide 27: Consolidated Historical Financial Performance: PAT
Consolidated Historical Financial Performance PAT (INR Mn) Summary ▪ Impact of Higher Cost profile in certain EPC contracts 2,083 1,950 1,954 ▪ Slowed execution of UP Contract ▪ Roha Facility Costs consequent to plant commissioning 1432 in FY 26 9.80% ▪ Impact of West Asia crisis 8.32% 7.61% Future
Slide 28: Consolidated Historical Financial Performance: Net Debt / Equity
Consolidated Historical Financial Performance Net Debt / Equity Summary FY23 FY24 FY25 FY26 ▪ Ratio within acceptable levels 0.01 ▪ Roha Capex financed by term loan (0.1) ▪ Lower Operating EBIDTA in FY 25 and FY 26 Future Actions (0.4) ▪ Revenue generation from Roha facility (0.6) ▪ Higher share of
Slide 29: Consolidated Historical Financial Performance: Return Ratios
Consolidated Historical Financial Performance Return Ratios Summary 32.5% 30.0% 26.9% ▪ Roha Plant Capex impact 22.0% ▪ West Asia crisis impacted gross working capital 24.7% 23.3% 21.1% 18.7% 14.3% ▪ Reduced Profitability 11.2% Future Actions FY22 FY23 FY24 FY25 FY26 ▪ Higher share of Industrial Pro
Slide 30: Consolidated Historical Financial Performance: Working Capital Days
Consolidated Historical Financial Performance Working Capital Days Summary 99 91 94 91 ▪ High proportion in Treatment Solution segment ▪ Impact of West Asia crisis in FY 26 Future Actions ▪ Increased business from Industrial Products, Lifecycle Services and Specialty Chemicals ▪ Increased share of I
Slide 31: Market Data
Market Data (Bloomberg – ION IN, Reuters – IONX.BO) 1 Y E AR SH AR E P R I C E MO VE ME N T ( U P T O 30 th J u n e 2026) 10% 0% -10% -20% -30% -40% -50% Jul-25 Aug-25 Sep-25 Oct-25 Nov-25 Dec-25 Jan-26 Feb-26 Mar-26 Apr-26 May-26 Jun-26 Ion Exchange Sensex P R I C E D ATA ( A s o n 3 0 t h J u n e
Slide 32: Disclaimer
Disclaimer Ion Exchange (India) Limited No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all e
Slide 33: www.ionexchangeglobal.com
www.ionexchangeglobal.com
Slide 34: Annexures
€ Annexures
Slide 35: Quarterly Standalone Segmental Breakup: Treatment Solutions
Quarterly Standalone Segmental Breakup Treatment Solutions INR Mn Q1-FY27 Performance Highlights 2,010 ▪ Revenue Growth of 16% 1,732 ▪ Dispatches to GCC resumed .. Pick up going forward ▪ Margins continue to be impacted by few legacy projects Future Growth Drivers 183 ▪ Existing backlog liquidation
Slide 36: Quarterly Standalone Segmental Breakup: Industrial Products
Quarterly Standalone Segmental Breakup Industrial Products INR Mn 1,055 Q1-FY27 Performance Highlights 885 ▪ Revenue Growth of 19% ▪ EBIT% up from 5.20% to 12.99% ▪ Strong performance by Standard Water Treatment Solutions and Membranes 137 46 Future Growth Drivers ▪ Manufacturing expansion for UF Me
Slide 37: Quarterly Standalone Segmental Breakup: Lifecycle Services
Quarterly Standalone Segmental Breakup Lifecycle Services INR Mn 587 Q1-FY27 Performance Highlights ▪ Revenue Growth of 25% 468 ▪ EBIT% increase from 8.55% to 10.56% ▪ Focus on O&M and Consumables Future Growth Drivers 40 62 ▪ Expanding solution offerings ▪ Retrofit business and BOO/BOOT Q1-FY26 Q1-
Slide 38: Quarterly Standalone Segmental Breakup: Specialty Chemicals
Quarterly Standalone Segmental Breakup Specialty Chemicals INR Mn 1,861 Q1-FY27 Performance Highlights 1,471 ▪ Revenue Growth of 27% ▪ EBIT down from 27.94% to 13.33% due to geopolitical impact ▪ Higher depreciation costs due to Roha facility capex 411 248 Future Growth Drivers ▪ Increased offtake f
Slide 39: Quarterly Standalone Segmental Breakup: Consumer Products
Quarterly Standalone Segmental Breakup Consumer Products INR Mn 1,124 Q1-FY27 Performance Highlights 843 ▪ Revenue Growth of 33% ▪ EBIT slightly up from -0.71% to -0.36% ▪ Strong growth across all key product lines Future Growth Drivers ▪ Softener growth ▪ Wellness product offerings (6) (4) ▪ New pr
Ion Exchange (India) — Q1 FY2026-27 Earnings Presentation on 6ix